Playing hardball, the Belgian brewer will ask the Securities and Exchange Commission for action that could force removal of A-B's current board and installation of a hand-picked slate that includes several high profile U.S. executives and Adolphus Busch IV. He has sounded receptive to considering InBev's takeover offer, which A-B's current board has rejected. Shareholders would have to approve the change.

The hardball move may indicate InBev won't raise its offer of $65 a share unless A-B is willing to negotiate, the Financial Times reports. Among the executives InBev wants on the board are several former heads of healthcare giants: Ron Dollens, the former chief executive of Guidant, Dr Ernest Mario, former chief executive of Glaxo, Hank McKinnell, former chief executive of Pfizer, and Paul Meister, the former chief financial officer of Fisher Scientific.

InBev’s nominees also include former Nabisco chief financial officer Jim Healey; former Trane chief financial officer Peter D’Aloia; former Pillsbury chief executive John Lilly; former Dun & Bradstreet chief executive and chairman Allan Loren; former Lockheed general counsel William Vinson; former ArvinMeritor chief executive Larry Yost; Houlihan Lokey managing director Marjorie Bowen; and Lawrence Wimbush, a law school professor and retired Korn Ferry senior partner.

Read the full Financial Times article.

The change would have to be approved by a majority of shareholders. Anheuser-Busch gets 10 days to respond. Read the full New York Times article.